Kiadis BV and NV Organon Enter Into a Discovery Collaboration
GRONINGEN and OSS, The Netherlands, May 25 /PRNewswire/ — Kiadis BV and
NV Organon announced today that both companies have entered into an
evaluation agreement centered around the use of Kiadis’ core on-line
screening technology, the BioSelact(TM), for the Reproductive Medicine
discovery program at Organon.
Under the terms of the collaboration, Organon will supply Kiadis with a
proprietary target. Financial details of the collaboration are not disclosed.
Kiadis will deliver Organon with novel active compounds against the target
utilizing its BioSelact(TM) technology. Organon is particularly interested in
the ability of Kiadis’ BioSelact(TM) technology to efficiently characterize
bioactive compounds present in complex chemical mixtures.
Ton Rijnders, Vice President Research Oss at Organon, said: “Organon has
selected the BioSelact(TM) technology because it may accelerate the discovery
programs by rapid on-line confirmation of new novel active compounds. This is
a great opportunity for Organon to evaluate the potential of the Kiadis
technology to identify new leads.”
Manja Bouman CEO of Kiadis, commented: “We are very pleased to start this
project together with Organon. We are excited and encouraged by the
confidence that Organon has shown by entering into this evaluation of
BioSelact(TM). This collaboration can be seen as a further validation of the
successful commercialization strategy of Kiadis and value of Kiadis’
technology.”
About Kiadis
Kiadis has developed the unique and proprietary BioSelact(TM) platform
technology, allowing for a revolutionary drug discovery approach which
greatly enhances lead discovery and optimization programs. The BioSelact(TM)
platform allows the highly efficient screening of every Compound source of
synthetic or natural origin on virtually all pharmaceutical target classes.
Kiadis has successfully applied its technology to pharmaceutical and
nutraceutical discovery programs.
About Organon
Organon - with shared head offices in Roseland, NJ, USA and Oss, The
Netherlands - creates, manufactures and markets prescription medicines that
improve the health and quality of human life. Through a combination of
independent growth and business partnerships, Organon strives to remain or
become one of the leading pharmaceutical companies in each of its core
therapeutic fields: reproductive medicine, psychiatry and anesthesia.
Organon products are sold in over 100 countries, of which more than 60
have an Organon subsidiary. Organon is the human health care business unit of
Akzo Nobel.
http://www.kiadis.com
http://www.organon.com
SOURCE Kiadis BV
